ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
湖南麥濟生物技術股份有限公司(臨時代碼)
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
52周最高:
- -
52周最低:
- -
股本:
- -
香港流通股本:
- -
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
市銷率:
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
新股消息 | 麥濟生物港股IPO招股書失效
智通财经
·
01/14
科學家創業9年,燒錢8億元!對賭上市倒計時僅剩1年,深陷專利糾紛的麥濟生物如何撐起26億元估值?
每日经济新闻
·
2025/12/23
三生國健專利狙擊麥濟生物,估值26億的IPO之路暗藏三重風險
新浪证券
·
2025/11/14
三生國健與麥濟生物專利戰再開打
滚动播报
·
2025/11/04
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91209"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"91209","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","market":"HK","secType":"STK","nameCN":"湖南麥濟生物技術股份有限公司(臨時代碼)","latestPrice":0,"timestamp":1770969600000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"02-13 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91209\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91209\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91209\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91209\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603668855","title":"新股消息 | 麥濟生物港股IPO招股書失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668855","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603668855?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 10:27","pubTimestamp":1768357655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,湖南麦济生物技术股份有限公司-B(简称:麦济生物)于2025年7月14日所递交的港股招股书满6个月,于2026年1月14日失效,递表时中金为其独家保荐人。招股书显示,麦济生物是一家处于注册临床阶段的生物制药公司,专注于发现、开发及商业化创新生物制剂,以解决有关过敏性及自身免疫疾病以及其他炎症与免疫性疾病方面尚未满足的医疗需求。自2016年成立以来,公司已自主研发并建立一条由八款创新候选产品组成的强大管线,包括核心产品MG-K10、关键产品MG-014及MG-013,以及五款其他候选产品。所有该等产品均为通过公司自有技术平台发现及开发的新一代长效抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91209"],"gpt_icon":0},{"id":"2593457143","title":"科學家創業9年,燒錢8億元!對賭上市倒計時僅剩1年,深陷專利糾紛的麥濟生物如何撐起26億元估值?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593457143","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593457143?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 09:51","pubTimestamp":1766454660,"startTime":"0","endTime":"0","summary":"临近年末,对递表港交所近半年却仍未进入聆讯的IPO公司而言,上市冲刺失败几率正在放大。公司今年7月14日向港交所提交上市申请书,截至目前尚未进入聆讯。自2016年成立以来,麦济生物已自主研发并建立一条由八款创新候选产品组成的管线。就在上个月,三生国健又提交了针对麦济生物一项核心专利无效宣告请求,是否会对MG-K10上市进程造成影响尚未可知。与此同时,麦济生物净亏损分别高达2.53亿元、","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-23/doc-inhctxhn8500511.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-23/doc-inhctxhn8500511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91209","161022"],"gpt_icon":0},{"id":"2583490526","title":"三生國健專利狙擊麥濟生物,估值26億的IPO之路暗藏三重風險","url":"https://stock-news.laohu8.com/highlight/detail?id=2583490526","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583490526?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 13:34","pubTimestamp":1763098440,"startTime":"0","endTime":"0","summary":"三生国健与麦济生物围绕IL-4R抗体专利的争夺战再度升级。11月3日,三生国健公开表示,已向国家知识产权局申请宣告麦济生物核心专利无效,直指其当家产品MG-K10的命脉。这场纠纷背后,不仅是两家药企的技术归属之争,更暴露了麦济生物在冲刺港交所之际面临的专利、财务与市场竞争三重压力。三生国健随后提起诉讼,指控其为“职务发明”。 麦济生物的财务状况同样令人担忧。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-14/doc-infxiwfa4569789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","91209","688336"],"gpt_icon":0},{"id":"2580209904","title":"三生國健與麥濟生物專利戰再開打","url":"https://stock-news.laohu8.com/highlight/detail?id=2580209904","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580209904?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 14:34","pubTimestamp":1762238040,"startTime":"0","endTime":"0","summary":" 三生国健与麦济生物的专利战有了新进展。 三生国健表示,2020年,麦济生物的另一项IL-4R专利被上海知识产权法院判决侵权。当时,三生国健起诉麦济生物侵犯其专利权,称涉案专利技术实为职务发明,应归公司所有。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-04/doc-infwfiev0519233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","91209","688336"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91209\",params:#limit:6,delay:false,,,undefined,":[]}}